After the World Health Organisation (WHO) approved Bharat Biotech's Covaxin for emergency use, medical journal Lancet has now stated that the made-in-India vaccine is 77.8 per cent effective against symptomatic Covid, as demonstrated by the phase 3 data. The efficacy data demonstrated 70.8 per cent protection against all variants of the SARS-CoV-2 virus.